A Controversial Move by the FDA: Restricting Vaccines Based on Unproven Claims
The Food and Drug Administration (FDA) has proposed a drastic shift in vaccine safety testing and approval processes, citing concerns about mRNA-based COVID-19 vaccines and their potential link to child deaths. This move, outlined in a memo by the agency's top vaccine regulator, Vinay Prasad, has sparked controversy and raised important questions about vaccine safety and access.
The memo, released in November 2025, attributes the deaths of at least 10 children to myocarditis, an inflammation of the heart muscle. However, it fails to provide solid evidence that the vaccines caused these deaths, relying instead on an internal review and reports to the Vaccine Adverse Event Reporting System (VAERS).
As a pediatric cardiologist who has studied the connection between COVID-19 vaccines and heart-related side effects in children, I find this allegation concerning. While rare, these side effects have been documented, but severe outcomes are even more uncommon. Yet, without compelling evidence, restricting vaccine access and changing established testing procedures could have severe repercussions.
Determining Cause of Death: A Complex Process
The FDA memo claims a direct link between COVID-19 immunization and the deaths of these children. As a clinician, I share the sentiment that no child should die from a routine vaccination. However, it is our duty as health professionals to rigorously investigate such incidents and uphold the highest standards of evidence.
If the FDA possesses evidence that national health agencies worldwide have overlooked - widespread child deaths due to myocarditis caused by the COVID-19 vaccine - it would be a game-changer. But so far, no such evidence has been presented.
A death reported to VAERS is a starting point, but it does not conclusively prove that the vaccine caused the death. To establish a causal link, FDA staff and physicians must align VAERS reports with physician assessments and data from other vaccine safety monitoring sources like PRISM and the Vaccine Safety Datalink.
It's important to note that most deaths logged only in VAERS for children who recently received vaccines have been incorrectly attributed to the vaccines, either accidentally or, in some cases, intentionally by anti-vaccine activists.
Heart-Related Side Effects and Vaccine Safety
Vinay Prasad, in his Substack and Twitter posts, has expressed concerns about the rate of severe cardiac side effects after COVID-19 vaccination, believing it to be underestimated. He advocates for stricter restrictions on these vaccines.
Studies suggest a risk of myocarditis ranging from 20 to 27 cases per million in young men who received the COVID-19 vaccine. However, these same studies indicate that unvaccinated individuals face a greater risk of heart problems after a COVID-19 infection compared to vaccinated individuals. Additionally, those who developed myocarditis after COVID-19 vaccination experienced fewer complications than those who developed it after a COVID-19 infection.
The U.S. vaccine safety infrastructure, including VAERS and the Vaccine Safety Datalink, has successfully identified vaccine-related dangers, including the rare but genuine safety issue with viral vector vaccines during the COVID-19 pandemic. These vaccines were found to cause blood clotting, leading to their formal recommendation for pause by the FDA in April 2021 and eventual removal from the market.
Death due to myocarditis from COVID-19 vaccination is extremely rare, and demonstrating such a link requires rigorous proof, including evidence of myocarditis, absence of other reasonable causes of death, and no additional causes of myocarditis. VAERS data alone cannot provide this level of certainty, and the FDA has not presented any other relevant data to support its claims.
The Problematic Vision for Future Vaccine Approvals
Currently, vaccines are tested for their ability to prevent disease and generate antibodies, which are crucial for fighting viruses and bacteria. For vaccines like COVID-19 and influenza, which need regular updates due to new strains, the FDA generally approves these updates based on their antibody generation capabilities, assuming their infection prevention abilities are comparable to previous generations.
The FDA memo proposes replacing these studies with numerous placebo-controlled trials, not just for COVID-19 vaccines but also for widely used influenza and pneumonia vaccines. While this may seem theoretically sound, it is not practical.
Influenza vaccines must be changed every season to account for viral mutations. Requiring new placebo-controlled trials annually would render the tested vaccine obsolete by the time it's approved, resulting in a massive waste of time and resources. Additionally, detecting vaccine-related myocarditis at such a low rate would require significantly larger clinical trials than those conducted for COVID-19 mRNA vaccine approval, incurring millions of dollars in additional costs and potentially delaying vaccine rollout, which could cost lives.
Placebo-controlled trials would involve comparing people who receive the updated vaccine with those who remain unvaccinated, which is considered unethical when an older version of the vaccine is available. Current scientific practice allows placebo comparisons only for brand-new vaccines.
While suspected vaccine deaths should be thoroughly investigated, stopping a vaccine for insufficient reasons can significantly erode public confidence. It is essential to investigate any claims of vaccine harm thoroughly and transparently.
Vaccine vs. Illness: Weighing the Risks
To accurately assess a vaccine's risks, it is crucial to compare its side effects with the effects of the illness it prevents. For COVID-19, data consistently shows that the disease is more dangerous. From August 2021 to July 2022, over 800 children in the U.S. died due to COVID-19, but very few deaths from COVID-19 vaccines in children have been verified worldwide. Furthermore, the disease causes many more heart-related side effects than the vaccine.
COVID-19 vaccination has been shown to reduce the risk of hospitalization by more than 70% and the risk of severe illness in adolescent children by 79%. It also dramatically reduces their risk of developing long COVID, a condition where symptoms like extreme fatigue or weakness persist for more than three months after a COVID-19 infection.
Reporting only the vaccines' risks without their benefits provides an incomplete picture. It is essential to consider the full spectrum of evidence when making decisions about vaccine safety and access.
Conclusion: A Call for Evidence-Based Decisions
The FDA's proposed changes to vaccine safety testing and approval processes are controversial and could have significant implications for vaccine access. While it is crucial to investigate suspected vaccine deaths, it is equally important to base decisions on solid evidence and maintain public confidence in vaccines and public health. As a medical professional, I urge the FDA to carefully consider the potential consequences of its actions and ensure that any changes are supported by robust scientific evidence.
